Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions
Systemic sclerosis (SSc) is a complicated multisystem disease which is characterized by the highest standardized mortality ratio among all systemic rheumatic diseases with no approved therapies so far. From a pathogenetic point of view it is generally considered that autoimmunity, vasculopathy and f...
Main Authors: | Dimitrios Daoussis, Stamatis-Nick Liossis |
---|---|
Format: | Article |
Language: | English |
Published: |
PCO Convin S.A.
2019-01-01
|
Series: | Mediterranean Journal of Rheumatology |
Subjects: | |
Online Access: | https://www.mjrheum.org/assets/files/792/file164_773.pdf |
Similar Items
-
Comparative Study of Mycophenolate Mofetil and Methotrexate in Graft-Versus-Host Disease Prophylaxis in Adult Recipients of Related and Unrelated Allo-HSCT
by: IS Moiseev, et al.
Published: (2018-12-01) -
Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment
by: Dorota Krasowska, et al.
Published: (2017-12-01) -
A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis
by: Annemarie Schorpion, et al.
Published: (2018-05-01) -
Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study
by: Kristofer Andréasson, et al.
Published: (2020-10-01) -
Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?: A mini-review
by: Alice Tung Wan Song, et al.